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deacetylase inhibitors, which restore histone acetylationPolyglutamine Diminishes
and upregulate gene transcriptions (Steffan et al., 2001).VEGF: Passage to Motor Although decreased transcription appears to be a plau-
sible explanation for the pathogenesis, little direct linkNeuron Death?
between CBP dysfunction and neurodegeneration has
been clarified in vivo. In addition, it remains unclear
which gene is responsible for neuronal cell death in each
Altered gene transcription has been implicated in the polyglutamine disease.
pathogenesis of polyglutamine-dependent neurode- Spinal and bulbar muscular atrophy (SBMA), or Ken-
generation. In this issue of Neuron, Sopher et al. dem- nedy’s disease, which is caused by an expanded CAG
onstrate that androgen receptors containing ex- repeat in the androgen receptor (AR) gene, was the first
panded polyglutamine cause decreased expression of disease to be identified as a polyglutamine disease (La
vascular endothelial growth factor (VEGF) by interfer- Spada et al., 1991). SBMA is an adult-onset lower motor
neuron disease characterized by proximal muscle atro-ing with cAMP response element binding protein bind-
phy, weakness, fasciculations, and bulbar involvement.ing protein (CBP), thereby contributing to the motor
In the central nervous system, the brainstem and theneuron degeneration in spinal and bulbar muscular at-
anterior horn are selectively involved. Besides motorrophy.
neuron degeneration, patients present with several sys-
temic complications: gynecomastia, hyperlipidemia,Expansion of a triplet nucleotide repeat is the molecular
and glucose intolerance. Since the loss of AR functionbasis for a variety of hereditary neuromuscular diseases.
does not result in neuromuscular phenotypes, the ex-At least nine neurodegenerative diseases result from
tended polyglutamine tract itself appears to render thea tedious trinucleotide CAG repeat, which encodes a
causative protein toxic, as documented in other polyglu-polyglutamine tract (reviewed in Zoghbi and Orr, 2000).
tamine diseases. The disruption of CBP-mediated tran-These disorders, called polyglutamine diseases, include
scription has also been implicated in the pathogenesisspinal and bulbar muscular atrophy (SBMA), Hunting-
of this disease (McCampbell et al., 2001). Despite aton’s disease (HD), spinocerebellar ataxias (SCA1, 2, 3,
common molecular basis, SBMA is distinct from other6, 7, and 17), and dentatorubral pallidoluysian atrophy
polyglutamine diseases in that males are exclusively(DRPLA). Several shared clinical and histopathological
affected. A transgenic mouse model of SBMA revealedfeatures seen in polyglutamine diseases imply a com-
that ligand-dependent nuclear translocation of themon pathogenesis. The patients suffer from slow pro-
pathogenic AR protein accounts for the gender-relatedgressive neuromuscular symptoms with the onset in
pathogenesis, leading to the development of a potentialadulthood. Although the causative genes are distinct,
hormonal therapy for this disorder (Katsuno et al., 2002).
selected subsets of neurons in the central nervous sys-
In this issue of Neuron, Sopher et al. (2004) report a
tem undergo degeneration in each disease. Histopatho-
new transgenic mouse model carrying human AR yeast
logical hallmarks are the loss of neurons in the affected artificial chromosome (YAC) with a prolonged CAG re-
area and the existence of characteristic intranuclear in- peat. Their study reconfirmed the importance of nuclear
clusions in the residual neuronal cells. These inclusions accumulation of aberrant AR and ligand-dependent
contain aggregates of the causative protein together pathophysiology in SBMA. Since the expression of the
with fundamental cellular components, providing a clue transgene is controlled by its own promoter, the mRNA
to the mechanisms causing neurodegeneration. Al- level of the mutant AR in this model is less than that in
though the precise role of these inclusions remains open previous mouse models using potent exogenous pro-
to debate, a large body of evidence suggests that the moters. This would account for the pathological distribu-
nuclear localization of aberrant polyglutamine protein is tion reminiscent of SBMA and the slow progression of
an essential step in the pathogenesis. motor disability. Among the conspicuous achievements
The perturbation of gene transcription is likely to be in this study is the finding that the transgenic mice reca-
among the most substantial nuclear events in the patho- pitulate the loss of lower motor neurons in SBMA.
physiology of polyglutamine diseases. This hypothesis Whereas histopathological studies of autopsy cases
emerged from the observation that cAMP response ele- with polyglutamine diseases show a tangible loss of
ment binding protein binding protein (CBP), a transcrip- neurons in lesions, a majority of transgenic mouse mod-
tional coactivator, is sequestrated into the polyglutam- els demonstrate neuromuscular disability without de-
ine inclusion (Nucifora et al., 2001). Furthermore, the tectable cell death (Zoghbi and Orr, 2000). This could
acetyltransferase activity of CBP is directly inhibited be explained by the short life span and excessive ex-
by the interaction with aberrant polyglutamine protein pression of the causative polyglutamine protein in these
(Steffan et al., 2001). In agreement with these findings, mouse models. Symptomatic phenotypes with normal
alteration of a wide range of gene expression has been cell populations may indicate that the pathophysiology
detected in mouse models of polyglutamine diseases of polyglutamine disease rises from the dysfunction of
(Sugars and Rubinsztein, 2003). It is of therapeutic sig- neurons. This hypothesis in turn indicates the reversibil-
nificance that polyglutamine-mediated neurodegenera- ity of the pathogenesis at the early stage of the diseases.
In support of this view, the interruption of mutant genetion in a Drosophila model of HD is alleviated by histone
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the peripheral nerve, and neurogenic muscular atrophy,
all of which are pathological features of human motor
neuron diseases. Moreover, the targeted disruption of
HRE results in the marked exacerbation of motor neuron
degeneration in transgenic mice carrying mutant super-
oxide dismutase 1 (SOD 1), the most frequent cause of
familial ALS (Lambrechts et al., 2003). The deleterious
effects of HRE deletion on motor neurons could be due
to the suppression of favorable effects of VEGF: en-
hancement of blood supply and direct neuroprotection.
Given that intraperitoneal administration of VEGF ame-
liorates ischemia-induced degeneration of spinal motor
neurons in the aberrant VEGF knockin mice (Lambrechts
et al., 2003), blood circulation insufficiency may cause
neuromuscular phenotypes. Since VEGF protects cul-
tured normal motor neurons from apoptotic stimuli, lossFigure 1. Possible Mechanism of VEGF-Related Motor Neuron De-
of these neurotrophic effects could also contribute togeneration in SBMA
the pathogenesis of motor neuron degeneration due toHypoxia-inducible factor 1 (HIF-1) binds to hypoxia-response ele-
HRE deletion.ment (HRE) in the promoter of vascular endothelial growth factor
(VEGF), upregulating its transcription. This transactivating activity The study of Sopher et al. shows that the reduction
of HIF-1 is facilitated through interaction with cAMP response ele- in the expression level of VEGF precedes the onset of
ment binding protein binding protein (CBP). In spinal and bulbar neurogenic muscular atrophy, suggesting that the tran-
muscular atrophy (SBMA), the pathogenic androgen receptor (AR) scriptional alteration is a trigger, rather than a conse-
containing expanded polyglutamine (polyQ) interacts with CBP, re-
quence, of neurodegeneration. The implication of VEGFsulting in decreased level of VEGF. These processes appear to
in SBMA is also backed by the observation that an exog-contribute to motor neuron degeneration in SBMA.
enous VEGF administration alleviates cytotoxicity in-
duced by pathogenic AR with expanded polyglutamine
in their cell model. In addition, CBP cotransfection aug-expression reversed the symptoms and histopathologi-
ments VEGF level in the same cultured motor neurons,cal features in a conditional mouse model of HD using a
implying that the transactivating ability of CBP is sup-tet-regulation system (Yamamoto et al., 2000). Although
pressed by an aberrant protein-protein interaction withthis observation justifies medical intervention to mildly
AR. This work sheds light on VEGF as a key player in theaffected or presymptomatic patients, elucidating the
pathogenesis of polyglutamine-induced motor neuronprecise mechanism giving rise to neuronal cell death
degeneration, providing another therapeutic target foris also essential for the development of therapies for
SBMA. The retrograde delivery of neurotrophic factorspolyglutamine diseases. The study of Sopher et al. ap-
ameliorates neurodegeneration in mouse models of mo-
pears to offer a striking insight into the pathophysiology
tor neuron diseases to some extent (Kaspar et al., 2003).
of polyglutamine-induced motor neuron death, in their
It should be of value to investigate whether VEGF admin-
revelation that the interaction between pathogenic AR
istration improves the polyglutamine-dependent patho-
and CBP results in a reduced expression of vascular genesis in the SMBA mouse model of Sopher et al.
endothelial growth factor (VEGF), which appears to con- Alternatively, the repressed transcription of VEGF in
tribute to the neurodegeneration in SBMA. SBMA mice suggests that chronic hypoxia aggravates
VEGF, first discovered as a factor enhancing vascular motor neuron degeneration, although its clinical implica-
permeability, plays a crucial role in physiological and tions have yet to be elucidated. Chronic ischemia, ag-
pathological angiogenesis. Diverse biological effects of gravated by lowered level of VEGF, appears to induce
VEGF are facilitated by its receptor, VEGF-2, also termed oxidative stress, which has been suggested to exacer-
kinase insert domain receptor (KDR). The gene expres- bate neurodegenerative processes. It thus seems possi-
sion of VEGF is drastically upregulated upon hypoxia ble that polyglutamine-induced pathophysiology could
in order to form new blood vessels. Hypoxia-inducible be ameliorated by antioxidative therapy, which should
factors, HIF-1 and HIF-2, mediate this cellular protec- be tested elsewhere.
tive response through binding to hypoxia-response ele- A great deal of effort has been made to clarify the
ment (HRE) in the promoter of VEGF. The transactivating exact mechanism causing neuronal dysfunction and the
activity of HIF-1 is facilitated through interaction with process leading to cell death in polyglutamine diseases.
transcriptional coactivators such as CBP (Figure 1). The Multiple pathophysiological steps may plunge neurons
depletion of a single allele of VEGF results in embryonic from dysfunction to death in the presence of an ex-
lethality, whereas lack of the HRE sequence in the VEGF panded polyglutamine tract. The transcriptional dysreg-
promoter leads to slowly progressive motor neuron de- ulation of VEGF is likely to play an important role in
generation (Oosthuyse et al., 2001). Knockin mice har- polyglutamine-induced motor neuron death, since the
boring a VEGF gene in which HRE is deleted demon- HRE-deleted mice also showed loss of spinal motor
strate a late-onset motor neuron disease resembling neurons (Oosthuyse et al., 2001). However, whether this
SBMA and amyotrophic lateral sclerosis (ALS), sug- hypothesis accounts for the whole pathogenesis of
gesting a pivotal role for VEGF in neurodegeneration. SBMA remains to be resolved. Given that multiple mech-
The low expression level of VEGF in these mice results anisms are involved in neurodegeneration, we need to
clarify which genes, regulated by CBP or other factors,in loss of spinal motor neurons, axonal degeneration in
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are responsible for the pathogenesis of polyglutamine forms of primary headache delivers the knockout mes-
sage that common neurobiological problems will yielddiseases. Such clarification would expand therapeutic
secrets to basic neuroscience for the ultimate good ofoptions for these devastating disorders.
patients.
Migraine aura consists of the neurological symptoms,Masahisa Katsuno and Gen Sobue
flashing jagged lights, pins and needles, or even weak-Department of Neurology
ness, that are so well recognized as preceding the attackNagoya University Graduate School of Medicine
proper in about 30% of patients. Familial hemiplegicNagoya 466-8550
migraine is a very rare form of migraine with prolongedJapan
aura in which an important manifestation is one-sided
weakness. So far, from a clinical viewpoint, it has beenSelected Reading
difficult to dissect its various forms. Mutations in the
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Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D., and Gage, F.H. tion, perhaps 30% of patients might be accounted for
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but this has raised the essential “so what” problem: howLa Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fisch-
does this elegant biology enlighten the clinical question,beck, K.H. (1991). Nature 352, 77–79.
why would this result in episodic, often profoundMcCampbell, A., Taye, A.A., Whitty, L., Penney, E., Steffan, J.S., and
weakness?Fischbeck, K.H. (2001). Proc. Natl. Acad. Sci. USA 98, 15179–15184.
Cortical spreading depression is a wave of excitationNucifora, F.C., Jr., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K.,
followed by inhibition that traverses the cortex at a rateYamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., et
al. (2001). Science 291, 2423–2428. of about 3–6 mm/min Pioneering work using human
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., brain blood flow measurements during migraine aura
Brusselmans, K., Van Dorpe, J., Hellings, P., Gorselink, M., Heymans, showed that the flow changes associated with aura also
S., et al. (2001). Nat. Genet. 28, 131–138. moved at this curious slow rate across the brain. Brain
Sopher, B.L., Thomas, P.S., Jr., LaFevre-Bernt, M.A., Holm, I.E., imaging (Hadjikhani et al., 2001) has carefully built a
Wilke, S.A., Ware, C.B., Jin, L.-W., Libby, R.T., Ellerby, L.M., and La case that migraine aura is the human version of the
Spada, A.R. (2004). Neuron 41, this issue, 687–699.
cortical spreading depression measured by electro-
Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., physiological methods in experimental animals (Laurit-Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M.,
zen, 1994). Studies of migraine aura in humans and corti-et al. (2001). Nature 413, 739–743.
cal spreading depression in experimental animals haveSugars, K.L., and Rubinsztein, D.C. (2003). Trends Genet. 19,
led to some very important questions: how is aura trig-233–238.
gered in humans, what role might the genetic mutationsYamamoto, A., Lucas, J.J., and Hen, R. (2000). Cell 101, 57–66.
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and last, what is the role of aura in migraine—is it the
pain trigger?
In this issue of Neuron, van den Maagdenberg and
colleagues report a Cacna1a knockin mouse with in-
creased susceptibility to cortical spreading depression.
Migraine Aura: A Knockin Mouse Using the R192Q mutation, which is clearly pathogenic
in humans (Ophoff et al., 1996), they very elegantlywith a Knockout Message
characterize with electrophysiological methods a gain-
of-function in cerebellar granule cells in culture from
homozygous mice. At the neuromuscular junction, end-
Migraine aura is a sometimes disabling disorder of the plate potentials, used as a measure of acetylcholine-
brain that involves significant neurological symptoms evoked postsynaptic depolarizations, were increased
in about 30% of patients. In this issue of Neuron, van by 240% under conditions of low Ca2 concentration,
den Maagdenberg et al. characterize a mouse with a representing enhanced activation in mutant mice com-
knockin mutation known to cause familial hemiplegic pared to wild-type mice. Using DC potential recordings
migraine and provide evidence that a lowered thresh- at the cortex, the authors also noted a lowered threshold
old to the triggering of CSD may account for the devas- for the induction and a remarkable 150% increase in the
tating phenotype of familial hemiplegic migraine. rate of propagation of cortical spreading depression.
Previous work using electrophysiological techniques
A good basic neuroscience paper can illustrate a funda- had shown a gain-of-function at the channel level but
mental principle, exploit new methods to open avenues a loss-of-function at the whole-cell level in transfected
for study, or even point the general direction to the cells that van den Maagdenberg and colleagues attri-
horizon where novel therapies will be found. This issue bute to overexpression. A general principle illustrated
of the Neuron has a contribution that does each of these by the new work is the absolute necessity for whole-
(van den Maagdenberg et al., 2004). Beginning to model animal studies to dissect the effects of mutations and
understand the integrated physiology of a disease. Rely-aspects of the most common of the severely disabling
